Publications
Detailed Information
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Cho, Nariya | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Kang, Keon Wook | - |
dc.contributor.author | Moon, Woo Kyung | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Park, In Ae | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Chung, June-Key | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:02:29Z | - |
dc.date.available | 2021-01-31T11:02:29Z | - |
dc.date.created | 2020-12-23 | - |
dc.date.created | 2020-12-23 | - |
dc.date.issued | 2011-10-20 | - |
dc.identifier.citation | BMC Cancer, Vol.11, p. 452 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 119681 | - |
dc.identifier.uri | https://hdl.handle.net/10371/172984 | - |
dc.description.abstract | Background: This study was aimed 1) to investigate the predictive value of FDG PET/CT (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) for histopathologic response and 2) to explore the results of FDG PET/CT by molecular phenotypes of breast cancer patients who received neoadjuvant chemotherapy. Methods: Seventy-eight stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. FDG PET/CTs were acquired before chemotherapy and after the first cycle of chemotherapy for evaluating early metabolic response. Results: The mean pre- and post-chemotherapy standard uptake value (SUV) were 7.5 and 3.9, respectively. The early metabolic response provided by FDG PET/CT after one cycle of neoadjuvant chemotherapy was correlated with the histopathologic response after completion of neoadjuvant chemotherapy (P = 0.002). Sensitivity and negative predictive value were 85.7% and 95.1%, respectively. The estrogen receptor negative phenotype had a higher pre-chemotherapy SUV (8.6 vs. 6.4, P = 0.047) and percent change in SUV (48% vs. 30%, P = 0.038). In triple negative breast cancer (TNBC), the pre-chemotherapy SUV was higher than in non-TNBC (9.8 vs. 6.4, P = 0.008). Conclusions: The early metabolic response using FDG PET/CT could have a predictive value for the assessment of histopathologic non-response of stage II/III breast cancer treated with neoadjuvant chemotherapy. Our findings suggest that the initial SUV and the decline in SUV differed based on the molecular phenotype. | - |
dc.language | 영어 | - |
dc.publisher | BioMed Central | - |
dc.title | Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/1471-2407-11-452 | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.identifier.wosid | 000296611200001 | - |
dc.identifier.scopusid | 2-s2.0-80054113983 | - |
dc.citation.startpage | 452 | - |
dc.citation.volume | 11 | - |
dc.identifier.sci | 000296611200001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Cho, Nariya | - |
dc.contributor.affiliatedAuthor | Kim, Jee Hyun | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Kang, Keon Wook | - |
dc.contributor.affiliatedAuthor | Moon, Woo Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Tae-You | - |
dc.contributor.affiliatedAuthor | Park, In Ae | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.contributor.affiliatedAuthor | Chung, June-Key | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | PATHOLOGICAL RESPONSE | - |
dc.subject.keywordPlus | F-18 FLUORODEOXYGLUCOSE | - |
dc.subject.keywordPlus | PRIMARY TUMOR | - |
dc.subject.keywordPlus | BLOOD-FLOW | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | STAGE-II | - |
dc.subject.keywordPlus | IN-SITU | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordAuthor | FDG PET | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | neoadjuvant chemotherapy | - |
dc.subject.keywordAuthor | molecular phenotype | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.